6533b851fe1ef96bd12a994e

RESEARCH PRODUCT

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

Jacky K. YuAlfonso IorioAndrea N. EdgintonSanjay AhujaMa Teresa ÁLvarez RománMa E. ArrietaMikko ArolaGiovanni BarillariVinod BalasaMark BelletruttiRuben Berrueco MorenoPhilippe BeurrierCristoph BidlingmaierVictor BlanchetteJan BlatnySantiago BonanadKelsey BroseDeborah BrownPaulette C. ByantMariana CanaroManuela CarvalhoCristina CatarinoMeera ChitlurErin CockrellPratima ChowdaryMarjon CnossenPeter CollinsMichial CoppensStacy CroteauDorina CultreraRaimundo De CristofaroEmmauelle De RaucourtDominique DesprezAmy DunnMagda El‐ekiabiBarbara Faganel KotnikKathleen FischerBrigit FrotscherSusana GarbieroRaquel Garrido RuizJoan GillCarmen Gomez Del CastilloSaskia GottsteinGiuseppe LassandroPaola GiordanoDaniel HartInga HegemannCedric HermansBaolai HuaNina HwangShannon JacksonPaula JamesOlga KatsarouKaan KavakliChristine KemptonKarim KentoucheOsman KhanRainer KobeltRebecca Kruse‐jarresEdward LaaneEric LarsonRiitta LassilaAdrienne LeeMan‐chiu PoonJennifer LissickSatu LangstromJohnny MahlanguMichael MakrisEmmanuela MarchesiniJose MateoPacual Marco VeraMarta MartorellTadashi MatsushitaSimon MccraeEva Mignot‐castellanoCaitlin MontcrieffPhilip MaesVeerle MondelarsMarlies BekartElena MoraJuan Cristóbal MoralesGuillaume MoureyMarie Ann BertrandMariasanta NapolitanoSergio SiragusaClaude NegrierDaniela NemeRitta NiinimakiJohannes OldenburgThilo AlbertDeborah OrnsteinMargarete OzeloJohn Carl PanettaEllis J. NeufeldStephanie P'ngKathelijne PeerlinckBerardino PollioClaire PouplardYves GruelAlessandra PrezottiVicky PriceFitri PrimacaktiMathieu PuyadePaolo RadossiLeslie RaffiniMargaret RagniSavita RangarajanMark T. RedingRobin ReidJose RestrepoJose RamirezMichael RechtManuel Rodriguez LopezArlette Ruiz‐sàezMahasen SalehAmy ShapiroAnjali SharathkumarAnna SelmecziMindy SimpsonTami SingletonMaria Sol CruzVeronica SotoMacgregor SteeleWerner StreifHao Wei SunBruce RitchieJing SunXiaqin FengTakashi SuzukiAsuza NagaoCliff TakemotoHeather TappJerry TeitelAlan TinmouthCourtney ThornburgAlberto TossetoOliver TurnstallCatherine VezinaBeth WarrenAllison WheelerJuan D. Wilches GutierrezJohn K.m. WuTung WynnRenchi YangGuy YoungEzio ZanonIrena Zupan

subject

medicine.medical_specialtyFactor concentrate610 Medicine & healthReview Article030204 cardiovascular system & hematologyHemophilia ADrug SubstitutionHemophilia BFactor IX03 medical and health sciencesDrug substitution0302 clinical medicinePharmacokineticsmedicineDosingIntensive care medicineFactor IXClotting factorOriginal Articles: Haemostasisfactor IXFactor VIIIlcsh:RC633-647.5business.industryDosing regimenlcsh:Diseases of the blood and blood-forming organsHematology3. Good healthOnline‐only Articlesfactor VIII3121 General medicine internal medicine and other clinical medicinedrug substitution10032 Clinic for Oncology and Hematologydrug substitution; factor IX; factor VIII; hemophilia A; hemophilia Bhemophilia Bhemophilia Abusiness030215 immunologymedicine.drug

description

Abstract The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhibitor development studies. Research on how best to switch concentrates with respect to dosing regimen are lacking, and currently a trial-and-error approach is used for dosing the new factor concentrate. In the future, studies looking at the predictability of pharmacokinetics (PK) of a new factor concentrate based on individual PK knowledge of the original factor concentrate may offer clinical benefit by providing a safer switching approach and protocol. Peer reviewed

yearjournalcountryeditionlanguage
2019-07-01
10.1002/rth2.12204https://hdl.handle.net/2078.1/224098